Zacks Research Reduces Earnings Estimates for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Equities researchers at Zacks Research dropped their Q1 2025 EPS estimates for Avanos Medical in a note issued to investors on Wednesday, March 19th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.19 for the quarter, down from their previous forecast of $0.29. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s Q2 2025 earnings at $0.29 EPS, Q4 2025 earnings at $0.42 EPS, Q1 2026 earnings at $0.31 EPS, Q3 2026 earnings at $0.39 EPS, Q4 2026 earnings at $0.49 EPS and FY2027 earnings at $1.43 EPS.

Separately, StockNews.com raised shares of Avanos Medical from a “hold” rating to a “buy” rating in a report on Wednesday.

Avanos Medical Stock Down 0.6 %

NYSE AVNS opened at $14.74 on Friday. The business has a fifty day moving average price of $15.84 and a 200 day moving average price of $18.79. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. The company has a market cap of $677.85 million, a P/E ratio of 43.34 and a beta of 1.17. Avanos Medical has a one year low of $14.25 and a one year high of $25.36.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.03. The company had revenue of $179.60 million for the quarter, compared to analysts’ expectations of $177.23 million. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%.

Insider Transactions at Avanos Medical

In other Avanos Medical news, SVP Kerr Holbrook sold 7,000 shares of the business’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $15.25, for a total transaction of $106,750.00. Following the transaction, the senior vice president now owns 82,047 shares of the company’s stock, valued at approximately $1,251,216.75. The trade was a 7.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 3.94% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of AVNS. Quarry LP purchased a new position in Avanos Medical during the third quarter worth about $42,000. KBC Group NV increased its holdings in shares of Avanos Medical by 63.0% during the 3rd quarter. KBC Group NV now owns 2,833 shares of the company’s stock worth $68,000 after buying an additional 1,095 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Avanos Medical during the 4th quarter valued at approximately $64,000. State of Wyoming lifted its holdings in Avanos Medical by 132.0% in the fourth quarter. State of Wyoming now owns 5,137 shares of the company’s stock valued at $82,000 after acquiring an additional 2,923 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Avanos Medical by 493.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,075 shares of the company’s stock worth $129,000 after acquiring an additional 6,714 shares during the period. Hedge funds and other institutional investors own 95.17% of the company’s stock.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.